Addressing right drug/right target/right patient in phase I studies to accelerate bench to clinical benefit time: ALK gene rearrangements and the development of PF-02341066 in NSCLC Meeting Abstract
| Authors: | Camidge, D. R.; Christensen, J.; Bang, Y. J.; Shaw, A. T.; Costa, D. B.; Salgia, R.; Dezube, B. J.; Shapiro, G. I.; Jänne, P. A.; Maki, R. G.; Solomon, B.; Kwak, E. L.; Tan, W.; Shreeve, S. M.; Wilner, K.; Clark, J. W.; Iafrate, A. J. |
| Abstract Title: | Addressing right drug/right target/right patient in phase I studies to accelerate bench to clinical benefit time: ALK gene rearrangements and the development of PF-02341066 in NSCLC |
| Meeting Title: | 1st AACR-IASLC Joint Conference on Molecular Origins of Lung Cancer – Prospects for Personalized Prevention and Therapy |
| Journal Title: | Journal of Thoracic Oncology |
| Volume: | 5 |
| Issue: | 6 Suppl.3 |
| Meeting Dates: | 2010 Jan 10-14 |
| Meeting Location: | San Diego, CA |
| ISSN: | 1556-0864 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2010-06-01 |
| Start Page: | S233 |
| Language: | English |
| ACCESSION: | ISI:000278102300053 |
| PROVIDER: | wos |
| DOI: | 10.1097/JTO.0b013e3181dc2e2b |
| Notes: | --- - Meeting Abstract: A24 - Suppl. 3 - "Source: Wos" |
